The Priority Review Voucher is granted AFTER a drug is approved by the FDA. The PRV entitles the NEXT drug to get reviewed faster. It can be sold -- that's how the 350 million figure was put on it. It's worth it to a big drug company to pay 350 million to get it approved faster if they have a drug that will sell for, say, a billion bucks a year.

What this means is we couldn't get a PRV until after the drug is approved. So it is quite a ways down the road.

Sorry for momentarily speaking in a Foghorn Leghorn voice in that last sentence. "